First trimester preeclampsia screening can help your doctor assess your risk profile earlier and more accurately. The sooner you know, the more you can do to prevent early onset preeclampsia or delay its onset.

In combination with other types of monitoring, PreeclampsiaScreen™ | T1 can give your doctor a higher level of accuracy in assessing your risk for early onset preeclampsia.

Preeclampsia: Knowing Your Risk Sooner Is Better.

Your doctor is testing you for your risk of developing early onset preeclampsia, a potentially serious condition that occurs in approximately 0.5% of all pregnancies. It's important to detect your risk for early onset preeclampsia as early as possible in your pregnancy so that if you are at risk, steps may be taken to protect your health and the health of your baby.

What Is Preeclampsia?

Preeclampsia is a sudden increase in blood pressure and protein in the urine after the 20th week of pregnancy. Preeclampsia can lead to eclampsia, or convulsions, posing serious health implications for mother and baby. Symptoms of preeclampsia may include:

What Is Early Onset Preeclampsia?

Early onset preeclampsia is defined as preeclampsia that results in the delivery of the baby before 34 weeks’ gestation. It can be more severe than preeclampsia and can be life-threatening in certain cases.

Although there is no cure for preeclampsia, medical research suggests that some steps may be taken during pregnancy to prevent or lessen the symptoms. These may include increased monitoring by your doctor, modified activity, bed rest, possible referral to specialty care, and the use of some medications, including aspirin.

Who’s at Risk for Preeclampsia?

Preeclampsia affects about 5%–7% of all pregnancies, and early onset preeclampsia accounts for a fraction of all the cases of preeclampsia (early onset preeclampsia affects about 0.5% of pregnancies). Risk factors for preeclampsia include:

Having one or more of these risk factors does not mean that you will develop preeclampsia, but it may point to the need for first trimester screening to help further evaluate and refine your risk.

A First Trimester Test Can Help.

PreeclampsiaScreen™ | T1 is an advanced blood test that helps determine your risk for early onset preeclampsia. It measures the presence of three biological “markers” of preeclampsia in the mother’s blood: PAPP-A (pregnancy-associated plasma protein-A); AFP (alpha fetoprotein); and PlGF (placental growth factor). When detected at certain levels, these markers can indicate that you are at a higher risk of developing early onset preeclampsia.

Your medical history and demographic information (e.g., height, weight, ethnicity and smoking) are also needed to provide an accurate risk assessment for early onset preeclampsia. Your doctor may also take one or both of these additional biophysical measurements:

What Does the Test Involve?

PreeclampsiaScreen™ | T1 can be ordered at the same time as other first trimester screening tests (such as screening for Down syndrome) and requires only a simple blood draw. Your doctor receives risk results in just 24-48 hours from sample receipt at the laboratory and can discuss them with you. Note that your doctor may choose to order other measurements such as MAP or UtAD-PI, which may involve a visit to an ultrasound lab.

What if the Test Shows that I am at Risk?

Most women are not at risk for early onset preeclampsia, but if your results show that you are, your doctor will discuss your level of risk and any steps to be taken to help manage the risk during your pregnancy.

The Sooner You Know, the Better.

Determining your risk for early onset preeclampsia during your first trimester can help protect your health and the health of your baby. The sooner you know, the sooner you and your doctor can take steps to prevent or delay the onset of preeclampsia. Your doctor can help you to decide what is best for you and your pregnancy.

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.